Utah Physician Indicted — Allegations Only
Indicted: April 2026. Status as of October 18, 2026: charged, not convicted.
What Prosecutors Allege
Federal prosecutors allege that a Utah physician obtained four unapproved compounds — retatrutide, BPC-157, TB-500 and ipamorelin — from Chinese suppliers, and administered them to more than 200 patients.
Retatrutide is an experimental Eli Lilly compound that has completed clinical trials but has never been approved for sale anywhere in the world. BPC-157 and TB-500 have, between them, essentially no completed human clinical trial record establishing efficacy for any diagnosis. Ipamorelin is a growth-hormone secretagogue. None of the four is an FDA-approved drug, and none is lawfully compoundable as of October 2026.
What an Indictment Is — and Is Not
An indictment is a grand jury’s finding that there is enough evidence to charge. It is not a conviction, not a finding of fact, and not a verdict. The physician is presumed innocent, and this page will be updated when the case resolves — in either direction. AllegedFraud’s standard for every case in this tracker: court outcomes are reported as outcomes; charges are reported as charges.
Why the Case Matters Either Way
The gray market is usually described as a website problem. This case, if the government proves it, is the website problem arriving inside a clinic: unapproved foreign-sourced compounds administered by a licensed professional to patients who reasonably believed they were receiving medical care. It is also the scenario behind the 20-state attorneys-general letter of September 2026 targeting Chinese peptide suppliers, and behind the roughly 130,000 vials seized at the border in the same period.
Part of the Peptide Gray Market tracker. Sources: U.S. Department of Justice indictment reporting, April 2026. Compiled October 18, 2026.